Delcath Systems/$DCTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Delcath Systems
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Ticker
$DCTH
Sector
Primary listing
Employees
96
Headquarters
Website
Delcath Systems Metrics
BasicAdvanced
$379M
193.75
$0.06
0.82
-
Price and volume
Market cap
$379M
Beta
0.82
52-week high
$18.23
52-week low
$8.08
Average daily volume
707K
Financial strength
Current ratio
10.875
Quick ratio
9.28
Long term debt to equity
0.835
Total debt to equity
0.946
Profitability
EBITDA (TTM)
5.178
Gross margin (TTM)
85.86%
Net profit margin (TTM)
3.18%
Operating margin (TTM)
7.14%
Effective tax rate (TTM)
23.95%
Revenue per employee (TTM)
$730,000
Management effectiveness
Return on assets (TTM)
4.15%
Return on equity (TTM)
3.57%
Valuation
Price to earnings (TTM)
193.748
Price to revenue (TTM)
5.063
Price to book
3.61
Price to tangible book (TTM)
3.61
Price to free cash flow (TTM)
91.967
Free cash flow yield (TTM)
1.09%
Free cash flow per share (TTM)
0.118
Growth
Revenue change (TTM)
491.35%
Earnings per share change (TTM)
-102.34%
3-year revenue growth (CAGR)
164.29%
10-year revenue growth (CAGR)
47.74%
3-year earnings per share growth (CAGR)
-75.87%
What the Analysts think about Delcath Systems
Analyst ratings (Buy, Hold, Sell) for Delcath Systems stock.
Bulls say / Bears say
Q2 2025 revenue jumped 210% compared to last year to reach $24.16 million, beating expectations by over 9%, and the company posted GAAP EPS of $0.07—a sharp turnaround from previous losses.
The company strengthened its U.S. commercial presence in Q2 2025 by activating three new treatment centers, now totaling 20 active sites plus 10 referral centers, expanding market reach for HEPZATO KIT.
The clinical pipeline broadened in December 2024 when the FDA cleared the Phase 2 IND for HEPZATO™ in liver-dominant metastatic colorectal cancer, opening access to a potential new market of 6,000-10,000 patients.
Margin pressure is rising as research and development expenses almost doubled year-over-year to $6.9 million, and selling, general and administrative expenses jumped to $11.4 million in Q2 2025, which increases the company's fixed costs if revenue growth slows.
There is significant product concentration risk because HEPZATO KIT made up about 93% of Q2 2025 revenue, making the company vulnerable to any setback with its only commercial therapy for metastatic uveal melanoma.
The stock is trading at a high valuation, with a price-to-sales ratio of about 7.1 versus the average of 3.3 for similar medical device companies, meaning there's less margin of safety with ongoing execution risks.
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Delcath Systems Financial Performance
Revenues and expenses
Delcath Systems Earnings Performance
Company profitability
Delcath Systems News
AllArticlesVideos
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 week ago
Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference
Business Wire2 months ago
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Delcath Systems stock?
Delcath Systems (DCTH) has a market cap of $379M as of September 15, 2025.
What is the P/E ratio for Delcath Systems stock?
The price to earnings (P/E) ratio for Delcath Systems (DCTH) stock is 193.75 as of September 15, 2025.
Does Delcath Systems stock pay dividends?
No, Delcath Systems (DCTH) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Delcath Systems dividend payment date?
Delcath Systems (DCTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Delcath Systems?
Delcath Systems (DCTH) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.